Indeed, conditional deletion of MOF in a mouse model of MLL-AF9-driven leukemogenesis, and accordingly the treatment with small molecules targeting MYST members, reduces acute myeloid leukemia (AML) cell proliferation [76]. This evidence concerns the gene KMT2A and acute myeloid leukemia.